Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

IRulya Therapeutics Inc.

CIK 1662774 IRLA·Biological Products · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Going concern 10-Q +226d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

IRulya Therapeutics Inc. no longer reports substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → No substantial-doubt conclusion identified

Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No substantial-doubt conclusion identified
Direction
eased
Prior filed
2026-08-14
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

Quince Therapeutics, Inc. told the SEC it could not file its annual report on time

Does not expect a significant change in results. 1 day past the statutory due date.

(the “Company”), was unable to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) within the prescribed time period as additional time is necessary to complete accounting procedures and prepare required disclosures, due to recent reductions in headcount and the impacts of the recently announced negative results of the Company’s Phase 3 clinical trial. As previously disclosed, the Company’s pivotal Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study, the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating…
Evidence
Anticipates significant change
No
Days past due date
1
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”), was unable to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) within the prescribed time period as additional time is necessary to complete accounting procedures and prepare required disclosures, due to recent reductions in headcount and the impacts of the recently announced negative results of the Company’s Phase 3 clinical trial. As previously disclosed, the Company’s pivotal Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study, the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.
Formerly
Quince Therapeutics, Inc.

Source filing ↗